CA2203083A1 - Gene and cdna involved in alzheimer's disease - Google Patents
Gene and cdna involved in alzheimer's diseaseInfo
- Publication number
- CA2203083A1 CA2203083A1 CA 2203083 CA2203083A CA2203083A1 CA 2203083 A1 CA2203083 A1 CA 2203083A1 CA 2203083 CA2203083 CA 2203083 CA 2203083 A CA2203083 A CA 2203083A CA 2203083 A1 CA2203083 A1 CA 2203083A1
- Authority
- CA
- Canada
- Prior art keywords
- disease
- alzheimer
- gene
- protein
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 76
- 108090000623 proteins and genes Proteins 0.000 title abstract description 64
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 102100024606 Protein phosphatase 1 regulatory subunit 1A Human genes 0.000 claims 1
- 101710163019 Protein phosphatase 1 regulatory subunit 1A Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 22
- 238000000034 method Methods 0.000 abstract description 21
- 108020004707 nucleic acids Proteins 0.000 abstract description 13
- 102000039446 nucleic acids Human genes 0.000 abstract description 13
- 208000015114 central nervous system disease Diseases 0.000 abstract description 7
- 230000014509 gene expression Effects 0.000 abstract description 6
- 206010015037 epilepsy Diseases 0.000 abstract description 5
- 238000001514 detection method Methods 0.000 abstract description 2
- 239000013598 vector Substances 0.000 abstract description 2
- 101150010487 are gene Proteins 0.000 abstract 1
- 230000035772 mutation Effects 0.000 description 17
- 210000000349 chromosome Anatomy 0.000 description 13
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 11
- 208000015756 familial Alzheimer disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 108700024394 Exon Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 102100029470 Apolipoprotein E Human genes 0.000 description 5
- 101710095339 Apolipoprotein E Proteins 0.000 description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 5
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 229960000367 inositol Drugs 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 102000054765 polymorphisms of proteins Human genes 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102100022033 Presenilin-1 Human genes 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 108060004006 inositol polyphosphate 5-phosphatase Proteins 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- -1 Iuciferase Proteins 0.000 description 3
- 108091092878 Microsatellite Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 101150089079 PS1 gene Proteins 0.000 description 3
- 108010050254 Presenilins Proteins 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 102000030582 inositol polyphosphate 5-phosphatase Human genes 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 2
- 108010025628 Apolipoproteins E Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 241000077989 Hiradonta chi Species 0.000 description 2
- 101000975401 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 3 Proteins 0.000 description 2
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 description 2
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 description 2
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101150023107 PS2 gene Proteins 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102000015499 Presenilins Human genes 0.000 description 2
- 101150031224 app gene Proteins 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- CIPFCGZLFXVXBG-ZIQZFLOESA-N inositol 1,3,4,5-tetrakisphosphate Chemical compound O[C@H]1[C@H](OP(O)(O)=O)[C@@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O CIPFCGZLFXVXBG-ZIQZFLOESA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 101150090724 3 gene Proteins 0.000 description 1
- 101710118202 43 kDa protein Proteins 0.000 description 1
- 108010078523 APP717 Proteins 0.000 description 1
- 208000012186 Alzheimer disease 3 Diseases 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 241000736839 Chara Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710102044 Envelope protein F13 homolog Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101000975421 Homo sapiens Inositol 1,4,5-trisphosphate receptor type 2 Proteins 0.000 description 1
- 102100024035 Inositol 1,4,5-trisphosphate receptor type 3 Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 102000006486 Phosphoinositide Phospholipase C Human genes 0.000 description 1
- 108010044302 Phosphoinositide phospholipase C Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000012098 association analyses Methods 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010019737 phosphoinositide 5-phosphatase Proteins 0.000 description 1
- 150000003906 phosphoinositides Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention discloses nucleic acid molecules encoding genes involved in CNS disorders such as Alzheimer's disease and epilepsy. Also disclosed are gene products, vectors and host cells suitable for expression of such gene products. Methods are providing for detecting the presence of a genes involved in Alzheimer's disease in human subjects and for treating humans suffering from Alzheimer's disease. Furthermore, markers which are associated with Alzheimer's disease are disclosed. Methods in kits for the detection of Alzheimer disease in a subject are additionally provided.
Description
' CA 02203083 1997-04-18 TITLE OF THE INVENTION
GENE AND cDNA INVOLVED IN ALZHEIMER'S
DISEASE
This invention relates generally to central nervous system (CNS) disorders. More particularly, this invention relates to Alzheimer's disease. In addition the invention relates to the diagnosis and treatment of Alzheimer's disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most con"non cause of progressive cognitive decline in the aged population. It causes 100 000 deaths each year in the United States where it is the fourth leading cause 15 of death. Alzheimer described amyloid plaques, neurofibrillary tangles and dementia that characterize AD in 1907. The usual presenting symptoms are deficits of recent memory often in association with with language and visuospati~l and attention problems.
To date, three genes have been identified that, when 20 mutated, can lead to early onset forms of AD and variation in a fourth one has been implicated as a risk or susceptibility factor for AD.
~amyloid precursorprotein The major protein of the senile plaques is ~amyloid (A~), a 39 to 43 amino acid peptide (Glenner and Wong, 1984; Masters 25 et al., 1985; ) derived from the ~-amyloid precursor protein (APP).
Plaques are found mainly in the hippocampus and in the temporal lobe cortex. APP was the first gene in which mutations were found to cause familial Alzheimer's disease (FAD). The APP gene, located on chromosome 21, has 19 exons and A~ is encoded by parts of exons 16 and 17 (Lemaire et al., 1989). Four mutations in the APP gene have been described (Chartier-Harlin et al., 1991; Fidani et al., 1992; Goate et a/., 1991; Karlinsky et al., 1992; Mullan et a/., 1992; Murrell et al., 1991;
Naruse et al., 1991; but they account for only 5% of published early-onset FAD .
Presenilins In 1992, Schellenberg etal (Schellenberg etal., 1992) reported a second locus causing early-onset AD on chromosome 14q24.3. A positional cloning strategy permitted the identification of a candidate gene, the S182 gene (Sherrington et al., 1995) later renamed presenilin-1 or PS1, that carried coding region mutations in families multiply affected by early-onset AD. The PS1 gene, composed of 10 exons, encodes a 467 amino acids protein with 7 to 10 transmembrane domains. More than 35 different mutations have been found in the PS1 gene in over 50 families of different ethnic origins (see van Broeckhoven, 1995 for review). The proportion of early-onset familial AD cases due to mutations in the PS1 gene is around 50%.
A genome -wide search conducted on another polulation with familial early-onset AD indicated another locus on chromosome 1 (Levy-Lahad et al.,1995a). The chromosome 1 FAD gene was cloned by virtue of its homology to PS1. The PS2 gene is composed of 12 exons and encodes a 448 amino acids protein (Levy-Lahad et al., 1995b). It shows 67% identity with the PS1 protein. Only two mutations have been identified in the PS2 gene suggesting that mutations in this gene are a rare cause of FAD protein (Levy-Lahad et al., 1995b; Rogaev et al., 1 995).
APO e4 The apolipoprotein E (APOE) gene, located on 5 chromosome 1 9q13.2 has been identified as a susceptibilty factor for AD
by genetic analysis of late-onset FAD pedigrees (Pericak-Vance et al., 1991). APO E is a major serum lipoprotein involved in cholesterol metabolism. Three common isoforms of APOE are encoded by alleles e2, e3, and e4 as a result of amino acids changes at codons 112 and 10 158. The APO e4 allele shows a dose dependent increase in risk for AD, apparently mediated through a decrease in the age of onset of disease (Corder et a/., 1993).
Not everyone having the susceptibility e4 allele will develop illness and many who lackcthe allele will also develop AD. APOE
15 testing is therefore not useful for predicting whether someone will dcvclop AD.
Research on the molecular ethiology of the a complex disease such as Alzheimer disease has been confounded by the large number of hereditary and environmental factors involved and by the 20 paucity of neuropathological and neurochemical studies on brains for affected individual. The finding of a linked marker involved in one hereditary form of Alzheimer disease will help to resolve the number of different genes underlying this corl,plex disease. This markers can be used eventually to provide genetic counselling in some affected fa,.,ilies.
25 Most importantly, the delineation of the genomic region containing Alzheimer disease gene will provide a mean to eventually discover and characterize this gene(s) in its encoded protein(s). The finding of link-markers will also make it possible to evaluate the role of gene(s) in this chromosomal region in the different levels of severity and onset of Alzheimer's disease.
The invention seeks to provide diagnosis and therapeutic tools for CNS disorders. Particularly the inventio seeks to provide diagnosis and therapeutic tools for Alzheimer's disease (AD). Herein, the term AD-related nucleic acid is not meant to be restrictiv eto AD only, 10 since other CNS disorders are herein shown to share co" "1)on genes and products thereof.
The present invention seeks to provide a nucleic acid segment isolated from human comprising at least a portion of a gene responsible for CNS disorders and particularly to AD. The AD-related 15 nucleic acid segment can be isolated using conventional methods which include for example YAC and BAC cloning, exon trapping and the like.
Such nucleic acids could also be synthesized chen, - ~"y. Having the AD-related nucleic acid segments of the present invention, parts thereof or oligos derived therefrom, other AD-related sequences using methods 20 described herein or other well known methods.
The invention also seeks to provide prokaryotic and eukaryotic expression vectors harboring the AD-related nucleic acid segment of the invention in an expressible from, and cells transformed with same. Such cells can serve a variet,v of purposes such as in vifro 25 models for the function of AD-related gene as well as for screening pharmaceutical compounds that could regulate the expression of the gene or the activity of the protein encoded therefrom. For example, such a cell, expressing a DNA sequence encoding a protein involved in proper neural function through the inositol phosphate pathway could serve to screen for pharmaceutical compounds that regulate neural function or inositol phosphate pathway.
An expression vector harboring AD-related nucleic acid segment or part thereof, can be used to obtain substantially pure protein.
Well-known vectors can be used to obtain large amounts of the protein which can then be purified by standard biochemical methods based on charge, molecular weight, solubility or affinity of the protein or alternatively, the protein can be purified by using gene fusion techniques such as GST fusion, which permits the purification of the protein of interest on a gluthathion column. Other types of purification methods or fusion proteins could also be used.
Antibodies both polyclonal and monoclonal can be prepared from the protein encoded by the Ad-related nucleic acid segment of the invention. Such antibodies can be used for a variety of purposes including affinity purification of the AD-related protein and diagnosis of a predisposition to AD or othre CNS disorders.
The AD-related nucleic acid segment, parts thereof or oligonucleotides derived therefrom, can further be used to identify differences between AD affected individuals and non AD-affected individuals. Similarly such segments can be used to identify a predisposiVon to AD in individulas. The AD-related sequences can further be used to obtain animal models for the study of CNS disorders.
Transgenic animals can be obtained. The functional activity of the AD
protein encoded by these nucleic acids, whether native or mutated, can be tested in in vitro or in vivo models.
The human AD-related sequences can be used in a DNA-based diagnostic assay to identify these individuals in the population who are at risk for the above mentioned types of diseases.
Further, the present invention seeks to provide the use of 5 the AD-related protein as a pharmacological target for modulating neuronal function and the like.
As used herein in the specifications and appended claims, the term "oligonucleotide" includes both oligomers of ribonucleotides and oligomers of deoxyribonucleotides.
The term high stringency hybridization conditions, as used herein and well known in the art, includes, for example: 5 X SSPE (1 X
SSPE is 10 mM Na-phosphate, pH 7.0; 0.18 M NaCI; 1 mM Na2 EDTA), 5 x Denhardt's solution (from a 100 X solution containing 2% BSA, 2%
Ficoll, 2% polyvinyl pyrollidone), 0.1% SDS, and 0,5 mg/ml denatured 15 salmon sperm DNA, at 65~C. Other conditions considered stringent include the use of formamide. An example of washing conditions for the blot includes, as a hnal stringency wash, an incubation of the blot at 65~C
in 0.1 X SSPE, 0.1% SDS for 1 hour.
In the specifications and appended claims, it is to be 20 understood that absolute complementarity between the primers and the template is not required. Any oligonucleotide having a sufficient complementarity with the template, so that a stable duplex is formed, is suitable. Since the formation of a stable duplex depends on the sequence and length of the oligonucleotide and its complementarity to the 25 template it hybridizes to, as well as the hybridization conditions, one skilled in the art may readily determine the degree of mismatching that . CA 02203083 1997-04-18 can be tolerated between the oligonucleotide and its target sequence for any given hybridization condition.
The invention features the means to identify factors that modulate the transcriptional activity of AD-related genes. Such factors 5 include, without being limited thereto, other kinases, phosphatases, nuclear receptors and transcriptionally regulatory proteins.
The present invention is also related to the use of AD-realted sequences of the present invention and functional derivatives thereof to screen for agents that modulate gene expression or the actity 10 of the products of these segments. Such modulators can be used as lead compounds to design or search drugs that can modulate the level of expression of these genes or the activity of their products.
Further, the present invention concerns a method for measuring the ability of a compound to act as an agonist or antagonist of 15 AD-related gene products comprising (a) contacting the compound with a transfected host cell expressing an AD-related sequence or mutant threof, and (b) comparing the level of activity of the product thereof or the level of expression of the AD related sequence. It is herein colltemplated to use the control regions of AD-related nucleic acids hooked to 20 heterologous genes such as any appropriate reporter gene (i.e.
Iuciferase, chloramphenicol acetyl transferase, green fluorescent protein or ~-galactosidase).
The invention is based on the results of an association study in recently founded populations in which a linkage disequilibrium 25 mapping of Alzheimer's disease was carried out. This analysis permitted the construction of haplotypes and enabled the identification of additional . CA 02203083 1997-04-18 markers in the vicinity of the most significant markers identified by the association analysis.
From these data, it was inferred that the Alzheimer~s disease loci comprise D10S212, D6S273, D1S228, D1S232, Gata89a1, D2S126, and D8S552.
Now that the location of Alzheimer's disease markers have been identified, other markers can be found using methods known in the art. Generally, primers are utilized which will identify markers associated with Alzheimer disease, for example (GD)n and RFLP markers.
The invention also extents to products useful for carrying out the assay, such as DNA probes (labelled or unlabelled), kits, and the like.
As broadest, the invention comprises detecting: the presence of genes involved in Alzheimer's disease by analysing human chromosomes, particularly chromosome 10, 6, 1, 9, 2 and 8 for further markers or DNA polymorphisms or the like linked to Alzheimer's dise~se.
The use RFLP's is only one preferred embodiment of detecting the polymorphisms. The most common methodology for detecting the presence of RLFP is to carry out resl-i~tion analysis using a given enzyme, perforrn a Southern procedure wHh a desiled probe and identify a given RFLP or RFLPs. The use RLFPs in linkage analysis and genetic testing is well known in the art (for example, see Gusella, US 4, 666,828 incorporated herein by reference in Donnus-Keller et al., 1987, Cell. 51:319-337). It should be clear that other methods to identify differences at the DNA level, or RNA level which are not related to RFLPs can also be used. These methods are well known in the art of human genetics. Any method capable of directing the polymorphisms can also be used. Techniques such as amplification of the desired regional , CA 02203083 1997-04-18 chro",osome coupled with direct sequencing, a location of polymorphisms and the chromosome by radio-labelling, fluorescent-labelling and enzyme-labelling can also be utilized.
DNA and/or RNA can be amplified using an amplificable 5 RNA sequence as a probe and q~-replicas.
The polynucleotide probes may be RNA or DNA and preferably DNA, and can be labelled by standard labelling techniques such as with the radio-label, enzyme-label, fluorescent-label, biotin-avidin label and the like, which allow for the detection after hybridization as 10 commonly known in the art.
Comparison of the RLFP or RLFPs for affected and unaffected individuals in the family line of the subject, with the RLFP or RLFPs (or other methods) for the subject under investigation will quickly reveal the presence or absence of the A!zheimer disease gene(s) in the 15 subject. Results of this expresses in terms of probability of presence of the Alzheimer disease gene(s) in the subject.
A number of methods are available to the person of ordinary skill to obtain other genetic sequences useful for probes in accordance with the present invention. Non limiting examples of such methods 20 include random DNA sequences which can be tested for their specificity, construction of DNA libraries and isolation of clones therefrom. The results of such methods is to identify a probe which can detect a polymorphism useful for testing for Alzheimer dise~se. The polymorphism must be found to be linked to Alzheimer disease or the other useful 25 markers in families studies, all to be adjacent to preexisting markers.
A particular probe can have any desired sequence as long as its is capable of identifying the polymorphism in the involved DNA
, CA 02203083 1997-04-18 regional or locus, it can be a DNA or RNA fragment, maybe synthesized chemical, enzymatically or isolated from a plasmid as well known to the person of ordinary skill. If a polymorphism is found in a gene product, such as a mRNA, the presence of that polymorphic mRNA may be 5 assayed directly with the probe, especially with antisense RNA probe.
Now that chromosomal location of the Alzheimer disease genes have been identified and defined to a small region, the region can be cloned and characterized by general methods known in the art.
The method lends itself readily to the formulation of kits 10 which can utilized in diagnosis.
Having now generally described the invention, the same will be understood by reference to certain specific examples that are provided here in exemplary form only and are not intended to be limiting unless othen,vise specified.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The human Type I phospl.atase, a critical determinant in AD
Data analysis from a genome wide screening of Al~l ,ei. ner's paliel1ls (23), using 700 microsatellites (positioned at an average of 4 to 20 7 cM), reveals seven (excluding ApoE) different regions in the genome which seem to be implicated in the physiopathology of AD. Genetic markers representing these regions have been sorted with relative P
values, and are ordered from greatest importance as follows: D10S212 > D6S273 > D1S228 > D1S232 > Gata89a1 > D2S126 > ApoE >
25 D8S552. Other potential sites of interest have also been detected in the genomic regions containing the Presenilin gene which have previously been shown to be implicated in AD pathology. The P values for these regions, however, were found to be weaker than those observed for the microsatellites listed above.
The microsatellite D10S212 coincides with the region of principal interest as revealed by fine mapping, and is found to be adjacent 5 to an intron of the inositol polyphosphate-5-phosphatase gene (IPP1).
This gene encodes a 43-Kda protein involved in the inositol phosphate pathway, its role being that of a downregulator within the cascade by inactivating inositol phosphate signalling molecules.
Biochemical messengers within most cells effect diverse 10 and complex responses that often depend on the mobilization of Ca2 from intracellular stores within the sarcoplasmic (in muscle) or endoplasmic reticulum (S-ER). Two types of S-ER Ca2 stores have been functionally characterized and identified by immunocyto-chemical localization of receptors (reviewed by Golovina and Blaustein, 1997), and 15 release of Ca2 from one of the stores requires myo-inositol 1,4,5-trisphosphate (IP3).
Two distinct human genes coding for 5-phosphatase (Types I and ll) have been cloned, and encode for 43-kDa and 75-kDa proteins respectively. The Type I protein is phosphorylated and activated by 20 protein kinase C, while Type ll is not phosphorylated by this kinase. 5-phosphatase enzymes hydrolyze three substrates involved in calcium mobilization: inositol 1,4,5-triphosphate (IP3), inositol cyclic 1:2,4,5-tetrakisphosphate and inositol 1,3,4,5-tetrakisphosphate (IP4).
The published cDNA of the inositol polyphosphate-5-phosphatase (IPP-1 ) is not complete, but we have cloned the full length cDNA from a humain brain cDNA library as well as part of the promoter ~ CA 02203083 1997-04-18 region, and have determined the intron/exon junction sequences. The genomic DNA corresponding to the exons and intron/exon junctions of the gene have been amplified using PCR and screened for mutations by the method of single strand conformation polymorphism (SSCP), from which 5 some nucleotide changes have been observed. All the polymorphisms except one are found within non-coding sequences, or in the third codon position in exons, which do not alter the amino acid residue. The only non- conservative mutation found is within the third exon of the gene, which changes the amino acid Iysine (MG) to arginine (AGG). However, 10 this transition is conservative if we consider the presence of a putative phosphorylation consensus sequence serine/threonine-X-lysine/arginine at that site. Experiments employing RT-PCR to analyze this polymorphism on the basis of differential expressio" levels within a set of patient samples did not show any differences.
Several studies suggest that alterations in the receptor-mediated phosphoinositide casc~de and cytosolic free calcium conceril,dlion [Ca2+]j are involved in the pathophysiology of aging, and in Alzheimer's disease. Cellular calcium ion signalling is induced by inositol phosphates formed directly or indirectly by the action of 20 phosphatidylinositol-specific phospholipase C on phosphdlidylinositol 4,5-bisphosphate in response to extracellular agonists (Berridge and Irvine, 1989; Bansal and Majerus, 1990; Rana and Hokin, 1990). These inositol phosphate signaling molecules are inactivated by inositol polyphosphate-5-phosphatase enzymes (5-phosphatase). Thus, by analogy with the 25 adenylate cyclase/cyclic nucleotide phosphodiesterase system (Ross and Gilman, 1990), phospholipase C forms the active signalling molecules, while the 5-phosphatase acts to degrade them. Changes in the activity of either of these enzymes may alter cellular responses to agonists.
One or more components of the inositol pathway are thus considered as excellent candidates for the development of a physiopathological model of Alzheimer disease. In light of the fact that the IP3R1-/- (from human chromosome 1) transgenic mice develop epilepsy, and that studies on human families affected by the JME reveal that the affected loci cosegregate with chromosome 6p21 where the homolog gene (IP3R3) is located, it appears highly probable that alterations in this pathway could be shared by different forms of genetic neurodisorders. If this proposed scenario is correct, we would expect to find in our population of AD some incidence of epilepsy, and this is indeed the case; the incidence of epilepsy in our examined population is signihcantly higher than that normally expected. These observations point tantilizingly towards the hypothesis that various alterations within the inositol biochemical pathway may result in vastly differing phenotypic manifestations, including epilepsy and Alzheimer's disease.
The 5-phospl1atase gene present on chromosome 10 was cloned and its cDNA and gene sequence is shown in Fig. 1.
The present invention therefore provides sequences of the human Type 1 5-phosphatase (IPP-1) and products thereof for diagnosis and l,eal"~e"l of CNS disorders such as AD. Having identified this gene from human, homologs thereof can be identified and isolated from other animals. Such homologs could also be used in accordance with thye present invention.
The present description refers to a number of documents, the contents of which are incorporated by reference.
~ CA 02203083 1997-04-18 REFERENCES
M.J.Berridge, R.F.lrvine. Inositol phosphates and cell signalling. Nature 341:197-205,1989.
V.A. Golovina, M.P.Blaustein. Spatially and functionally distinct Ca+
stores in sarcoplasmic and endoplasmic reticulum. Science 275:1643-1648, 1997.
10 K.M. Laxminarayan, B.K. Chan,T.Tetaz, P.l. Bird, C.A. Mitchell.
Characterization of a cDNA encoding the 43-kDa membrane-associated inositol-polyphosphate 5-phosphatase. J. Biol. Chem. 269: 17305-17310, 1994.
15 A.W. Liu, A.V. Delgado-Escueta, J.M. Serratosa, M.E. Alonso, M.T.
Medina, M.N. Gee, S. Cordova, H.Z. Zhao, J.M. Spellman, J.R. Ramos Peek, F. Rubio Donnadieu, R.S.Sparkes. Juvenile Myoclonic Epilepsy locus in chromosome 6p21.2-p11: Linkage to convulsions and electroencephalography trait. Am.J.Hum.Genet. 57:368-381, 1995.
A.R. Maranto. Primary structure, ligand binding, and localization of the human type 3 Inositol 1,4,5-Trisphosphate Receptor expressed in i"tesli"al epithelium. J. Biol. Chem 269:1222-1230,1994.
25 M. Matsumoto, T. Nakagawa, T. Inoue, E. Nagata, K. Tanaka, H. Takano, O. Minowa, J. Kuno, S. Sakakibara, M. Yamada, H. Yoneshima, A.
Miyawaki, Y. Fukuuchi, T. Furuichi, H. Okano, K. Mikoshiba, T. Noda.
Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature 379; 168-171,1996.
T.S. Ross, A.B. Jefferson, C.A. Mitchell, P.W. Majerus. Cloning and expression of human 75-kDa Inositol Polyphosphate-5-phosphatase. J.
Biol. Chem. 266:20283-20289, 1991.
35 M. Yamamoto-Hino, T. Sugiyama, K. Hikichi, M.G. Mattei, K. Hasegawa, S. Sekine, K. Sakurada, A. Miyawaki, T. Furuichi, M. Hasegawa, K.Mikoshiba. Cloning and characterization of human type 2 and type 3 Inositol 1,4,5-Trisphosphate receptors. Receptors and Channels 2:9-22, 1994.
. CA 02203083 1997-04-18 L.T. Young, S.J. Kish,P.P. Li, J.J. Warsh. Decreased brain H3 inositol 1,4,5-trisphosphate binding in Alzheimer's disease. Neuroscience Letters, 94: 198-202,1988.
5 M. C. Chartier-Harlin, F. Crawford, H. Houlden, A. Warren, D. Hughes, L.
Fidani, A. Goate, M. Rossor, P. Roques, J. Hardy ef al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353: 844-846 (1991).
10 E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C.
Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance.
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921 -923 (1993).
15 L. Fidani, K. Rooke, M. C. Chartier-Harlin, D. Hughes, R. Tanzi, M.
Mullan, P. Roques, M. Rossor, J. Hardy, A. Goate. Screening for mutations in the open reading frame and pro",oter of the beta-amyloid precursor protein gene in familial Alzheimer's disease: idenlific~lion of a further family with APP717 Val-~lle. Hum. Mol. Genet. 1: 165-168 (1992).
G. G. Glenner, C. W. Wong. Alzheimer's disease: initial report of the purification and chara~;te,i~dlion of a novel cerebrov~scul~r amyloid protein. Biochem. Biophys. Res. Commun.120: 885-890 (1984).
A. Goate, M. C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, L.
Fidani, L. Giuffra, A. Haynes, N. Irving, L. James ef al. Segr~yalion of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706 (1991).
J. Kang, H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K.
H. Grzeschik, G. Multhaup, K. Beyreuther, B. Muller-Hill. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
H. Karlinsky, G. Vaula, J. L. Haines, J. Ridgley, C. Bergeron, M. Mortilla, R. G. Tupler, M. E. Percy, Y. Robitaille, N. E. Noldy et a/. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the beta-amyloid precursor protein gene. Neurology 42: 1445-1453 (1992).
' CA 02203083 1997-04-18 H. G. Lemaire, J. M. Salbaum, G. Multhaup, J. Kang, R. M. Bayney, A.
Unterbeck, K. Beyreuther, B. Muller-Hill. The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons.
Nucleic Acids Res. 17: 517-522 (1989).
E. Levy-Lahad, E. M. Wjsman, E. Nemens, L. Anderson, K. A. Goddard, J. L. Weber, T. D. Bird and G. D. Schellenberg. A familial Alzheimer's disease locus on chromosome 1. Science 269: 970-973 (1995a) 10 E. Levy-Lahad, W. Wasco, P. Poorkaj, D. M. Romano, J. Oshima, W. H.
Pettingell, C. E. Yu, P. D. Jondro, S. D. Schmidt, K. Wang et al.
Candidate gene for the chromosome 1 ramilial Alzheimer's disease locus.
Science 269: 973-977 (1995b).
15 C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, K. Beyreuther. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U S A 82: 4245-9. (1985).
M. Mullan, H. Houlden, M. Windelspecht, L. Fidani, C. Lombardi, P. Diaz, 20 M. Rossor, R. Crook, J. Hardy, K. Duff et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat. Genet. 2: 340-342 (1992).
J. Murrell, M. Farlow, B. Ghetti, M. D. Benson. A mutation in the amyloid 25 precursor protein associated with hereditary Alzheimer's disease.
Science 254: 97-99 (1991).
S. Naruse, S. lgarashi, H. Kobayashi, K. Aoki, T. Inuzuka, K. Kaneko, T.
Shimizu, K. Iihara, T. Kojima, T. Miyatake etal. Mis-sense mutation Val-30 lle in exon 17 of amyloid precursor protein gene in Japanese familialAlzheimer'sdisease. Lancet337:978-979 (1991).
M. A. Pericak-Vance, J. L. Bebout, P. C. Gaskell, L. H. Yamaoka, W. Y.
Hung, M. J. Alberts, A. P. Walker, R. J. Bartlett, C. A. Haynes, K. A.
35 Welsh et al. Linkage studies in familial Alzheimer disease: evidence for chromosome19 linkage. Am J Hum Genet 48: 1034-50 (1991).
E. l. Rogaev, R. Sherrington, E. A. Rogaeva, G. Levesque, M. Ikeda, Y.
Liang, H. Chi, C. Lin, K. Holman, T. Tsuda et al. Familial Alzheimer's 40 disease in kindreds with missense mutations in a gene on chromosome , CA 02203083 1997-04-18 -1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778 (1995).
G. D. Schellenberg, T. D. Bird, E. M. Wijsman, H. T. Orr, L. Anderson, E.
5 Nemens, J. A. White, L. Bonnycastle, J. L. Weber, M. E. Alonso et al.
Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258: 668-671 (1992).
10 R. Sherrington, E. l. Rogaev, Y. Liang, E. A. Rogaeva, G. Levesque, M.
Ikeda, H. Chi, C. Lin, G. Li, K. Holman et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760 (1995) 15 C. van Broeckhoven. Presenilins and Alzheimer's disease. Nat. Genet.
11: 230-232 (1995).
GENE AND cDNA INVOLVED IN ALZHEIMER'S
DISEASE
This invention relates generally to central nervous system (CNS) disorders. More particularly, this invention relates to Alzheimer's disease. In addition the invention relates to the diagnosis and treatment of Alzheimer's disease.
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most con"non cause of progressive cognitive decline in the aged population. It causes 100 000 deaths each year in the United States where it is the fourth leading cause 15 of death. Alzheimer described amyloid plaques, neurofibrillary tangles and dementia that characterize AD in 1907. The usual presenting symptoms are deficits of recent memory often in association with with language and visuospati~l and attention problems.
To date, three genes have been identified that, when 20 mutated, can lead to early onset forms of AD and variation in a fourth one has been implicated as a risk or susceptibility factor for AD.
~amyloid precursorprotein The major protein of the senile plaques is ~amyloid (A~), a 39 to 43 amino acid peptide (Glenner and Wong, 1984; Masters 25 et al., 1985; ) derived from the ~-amyloid precursor protein (APP).
Plaques are found mainly in the hippocampus and in the temporal lobe cortex. APP was the first gene in which mutations were found to cause familial Alzheimer's disease (FAD). The APP gene, located on chromosome 21, has 19 exons and A~ is encoded by parts of exons 16 and 17 (Lemaire et al., 1989). Four mutations in the APP gene have been described (Chartier-Harlin et al., 1991; Fidani et al., 1992; Goate et a/., 1991; Karlinsky et al., 1992; Mullan et a/., 1992; Murrell et al., 1991;
Naruse et al., 1991; but they account for only 5% of published early-onset FAD .
Presenilins In 1992, Schellenberg etal (Schellenberg etal., 1992) reported a second locus causing early-onset AD on chromosome 14q24.3. A positional cloning strategy permitted the identification of a candidate gene, the S182 gene (Sherrington et al., 1995) later renamed presenilin-1 or PS1, that carried coding region mutations in families multiply affected by early-onset AD. The PS1 gene, composed of 10 exons, encodes a 467 amino acids protein with 7 to 10 transmembrane domains. More than 35 different mutations have been found in the PS1 gene in over 50 families of different ethnic origins (see van Broeckhoven, 1995 for review). The proportion of early-onset familial AD cases due to mutations in the PS1 gene is around 50%.
A genome -wide search conducted on another polulation with familial early-onset AD indicated another locus on chromosome 1 (Levy-Lahad et al.,1995a). The chromosome 1 FAD gene was cloned by virtue of its homology to PS1. The PS2 gene is composed of 12 exons and encodes a 448 amino acids protein (Levy-Lahad et al., 1995b). It shows 67% identity with the PS1 protein. Only two mutations have been identified in the PS2 gene suggesting that mutations in this gene are a rare cause of FAD protein (Levy-Lahad et al., 1995b; Rogaev et al., 1 995).
APO e4 The apolipoprotein E (APOE) gene, located on 5 chromosome 1 9q13.2 has been identified as a susceptibilty factor for AD
by genetic analysis of late-onset FAD pedigrees (Pericak-Vance et al., 1991). APO E is a major serum lipoprotein involved in cholesterol metabolism. Three common isoforms of APOE are encoded by alleles e2, e3, and e4 as a result of amino acids changes at codons 112 and 10 158. The APO e4 allele shows a dose dependent increase in risk for AD, apparently mediated through a decrease in the age of onset of disease (Corder et a/., 1993).
Not everyone having the susceptibility e4 allele will develop illness and many who lackcthe allele will also develop AD. APOE
15 testing is therefore not useful for predicting whether someone will dcvclop AD.
Research on the molecular ethiology of the a complex disease such as Alzheimer disease has been confounded by the large number of hereditary and environmental factors involved and by the 20 paucity of neuropathological and neurochemical studies on brains for affected individual. The finding of a linked marker involved in one hereditary form of Alzheimer disease will help to resolve the number of different genes underlying this corl,plex disease. This markers can be used eventually to provide genetic counselling in some affected fa,.,ilies.
25 Most importantly, the delineation of the genomic region containing Alzheimer disease gene will provide a mean to eventually discover and characterize this gene(s) in its encoded protein(s). The finding of link-markers will also make it possible to evaluate the role of gene(s) in this chromosomal region in the different levels of severity and onset of Alzheimer's disease.
The invention seeks to provide diagnosis and therapeutic tools for CNS disorders. Particularly the inventio seeks to provide diagnosis and therapeutic tools for Alzheimer's disease (AD). Herein, the term AD-related nucleic acid is not meant to be restrictiv eto AD only, 10 since other CNS disorders are herein shown to share co" "1)on genes and products thereof.
The present invention seeks to provide a nucleic acid segment isolated from human comprising at least a portion of a gene responsible for CNS disorders and particularly to AD. The AD-related 15 nucleic acid segment can be isolated using conventional methods which include for example YAC and BAC cloning, exon trapping and the like.
Such nucleic acids could also be synthesized chen, - ~"y. Having the AD-related nucleic acid segments of the present invention, parts thereof or oligos derived therefrom, other AD-related sequences using methods 20 described herein or other well known methods.
The invention also seeks to provide prokaryotic and eukaryotic expression vectors harboring the AD-related nucleic acid segment of the invention in an expressible from, and cells transformed with same. Such cells can serve a variet,v of purposes such as in vifro 25 models for the function of AD-related gene as well as for screening pharmaceutical compounds that could regulate the expression of the gene or the activity of the protein encoded therefrom. For example, such a cell, expressing a DNA sequence encoding a protein involved in proper neural function through the inositol phosphate pathway could serve to screen for pharmaceutical compounds that regulate neural function or inositol phosphate pathway.
An expression vector harboring AD-related nucleic acid segment or part thereof, can be used to obtain substantially pure protein.
Well-known vectors can be used to obtain large amounts of the protein which can then be purified by standard biochemical methods based on charge, molecular weight, solubility or affinity of the protein or alternatively, the protein can be purified by using gene fusion techniques such as GST fusion, which permits the purification of the protein of interest on a gluthathion column. Other types of purification methods or fusion proteins could also be used.
Antibodies both polyclonal and monoclonal can be prepared from the protein encoded by the Ad-related nucleic acid segment of the invention. Such antibodies can be used for a variety of purposes including affinity purification of the AD-related protein and diagnosis of a predisposition to AD or othre CNS disorders.
The AD-related nucleic acid segment, parts thereof or oligonucleotides derived therefrom, can further be used to identify differences between AD affected individuals and non AD-affected individuals. Similarly such segments can be used to identify a predisposiVon to AD in individulas. The AD-related sequences can further be used to obtain animal models for the study of CNS disorders.
Transgenic animals can be obtained. The functional activity of the AD
protein encoded by these nucleic acids, whether native or mutated, can be tested in in vitro or in vivo models.
The human AD-related sequences can be used in a DNA-based diagnostic assay to identify these individuals in the population who are at risk for the above mentioned types of diseases.
Further, the present invention seeks to provide the use of 5 the AD-related protein as a pharmacological target for modulating neuronal function and the like.
As used herein in the specifications and appended claims, the term "oligonucleotide" includes both oligomers of ribonucleotides and oligomers of deoxyribonucleotides.
The term high stringency hybridization conditions, as used herein and well known in the art, includes, for example: 5 X SSPE (1 X
SSPE is 10 mM Na-phosphate, pH 7.0; 0.18 M NaCI; 1 mM Na2 EDTA), 5 x Denhardt's solution (from a 100 X solution containing 2% BSA, 2%
Ficoll, 2% polyvinyl pyrollidone), 0.1% SDS, and 0,5 mg/ml denatured 15 salmon sperm DNA, at 65~C. Other conditions considered stringent include the use of formamide. An example of washing conditions for the blot includes, as a hnal stringency wash, an incubation of the blot at 65~C
in 0.1 X SSPE, 0.1% SDS for 1 hour.
In the specifications and appended claims, it is to be 20 understood that absolute complementarity between the primers and the template is not required. Any oligonucleotide having a sufficient complementarity with the template, so that a stable duplex is formed, is suitable. Since the formation of a stable duplex depends on the sequence and length of the oligonucleotide and its complementarity to the 25 template it hybridizes to, as well as the hybridization conditions, one skilled in the art may readily determine the degree of mismatching that . CA 02203083 1997-04-18 can be tolerated between the oligonucleotide and its target sequence for any given hybridization condition.
The invention features the means to identify factors that modulate the transcriptional activity of AD-related genes. Such factors 5 include, without being limited thereto, other kinases, phosphatases, nuclear receptors and transcriptionally regulatory proteins.
The present invention is also related to the use of AD-realted sequences of the present invention and functional derivatives thereof to screen for agents that modulate gene expression or the actity 10 of the products of these segments. Such modulators can be used as lead compounds to design or search drugs that can modulate the level of expression of these genes or the activity of their products.
Further, the present invention concerns a method for measuring the ability of a compound to act as an agonist or antagonist of 15 AD-related gene products comprising (a) contacting the compound with a transfected host cell expressing an AD-related sequence or mutant threof, and (b) comparing the level of activity of the product thereof or the level of expression of the AD related sequence. It is herein colltemplated to use the control regions of AD-related nucleic acids hooked to 20 heterologous genes such as any appropriate reporter gene (i.e.
Iuciferase, chloramphenicol acetyl transferase, green fluorescent protein or ~-galactosidase).
The invention is based on the results of an association study in recently founded populations in which a linkage disequilibrium 25 mapping of Alzheimer's disease was carried out. This analysis permitted the construction of haplotypes and enabled the identification of additional . CA 02203083 1997-04-18 markers in the vicinity of the most significant markers identified by the association analysis.
From these data, it was inferred that the Alzheimer~s disease loci comprise D10S212, D6S273, D1S228, D1S232, Gata89a1, D2S126, and D8S552.
Now that the location of Alzheimer's disease markers have been identified, other markers can be found using methods known in the art. Generally, primers are utilized which will identify markers associated with Alzheimer disease, for example (GD)n and RFLP markers.
The invention also extents to products useful for carrying out the assay, such as DNA probes (labelled or unlabelled), kits, and the like.
As broadest, the invention comprises detecting: the presence of genes involved in Alzheimer's disease by analysing human chromosomes, particularly chromosome 10, 6, 1, 9, 2 and 8 for further markers or DNA polymorphisms or the like linked to Alzheimer's dise~se.
The use RFLP's is only one preferred embodiment of detecting the polymorphisms. The most common methodology for detecting the presence of RLFP is to carry out resl-i~tion analysis using a given enzyme, perforrn a Southern procedure wHh a desiled probe and identify a given RFLP or RFLPs. The use RLFPs in linkage analysis and genetic testing is well known in the art (for example, see Gusella, US 4, 666,828 incorporated herein by reference in Donnus-Keller et al., 1987, Cell. 51:319-337). It should be clear that other methods to identify differences at the DNA level, or RNA level which are not related to RFLPs can also be used. These methods are well known in the art of human genetics. Any method capable of directing the polymorphisms can also be used. Techniques such as amplification of the desired regional , CA 02203083 1997-04-18 chro",osome coupled with direct sequencing, a location of polymorphisms and the chromosome by radio-labelling, fluorescent-labelling and enzyme-labelling can also be utilized.
DNA and/or RNA can be amplified using an amplificable 5 RNA sequence as a probe and q~-replicas.
The polynucleotide probes may be RNA or DNA and preferably DNA, and can be labelled by standard labelling techniques such as with the radio-label, enzyme-label, fluorescent-label, biotin-avidin label and the like, which allow for the detection after hybridization as 10 commonly known in the art.
Comparison of the RLFP or RLFPs for affected and unaffected individuals in the family line of the subject, with the RLFP or RLFPs (or other methods) for the subject under investigation will quickly reveal the presence or absence of the A!zheimer disease gene(s) in the 15 subject. Results of this expresses in terms of probability of presence of the Alzheimer disease gene(s) in the subject.
A number of methods are available to the person of ordinary skill to obtain other genetic sequences useful for probes in accordance with the present invention. Non limiting examples of such methods 20 include random DNA sequences which can be tested for their specificity, construction of DNA libraries and isolation of clones therefrom. The results of such methods is to identify a probe which can detect a polymorphism useful for testing for Alzheimer dise~se. The polymorphism must be found to be linked to Alzheimer disease or the other useful 25 markers in families studies, all to be adjacent to preexisting markers.
A particular probe can have any desired sequence as long as its is capable of identifying the polymorphism in the involved DNA
, CA 02203083 1997-04-18 regional or locus, it can be a DNA or RNA fragment, maybe synthesized chemical, enzymatically or isolated from a plasmid as well known to the person of ordinary skill. If a polymorphism is found in a gene product, such as a mRNA, the presence of that polymorphic mRNA may be 5 assayed directly with the probe, especially with antisense RNA probe.
Now that chromosomal location of the Alzheimer disease genes have been identified and defined to a small region, the region can be cloned and characterized by general methods known in the art.
The method lends itself readily to the formulation of kits 10 which can utilized in diagnosis.
Having now generally described the invention, the same will be understood by reference to certain specific examples that are provided here in exemplary form only and are not intended to be limiting unless othen,vise specified.
DESCRIPTION OF THE PREFERRED EMBODIMENT
The human Type I phospl.atase, a critical determinant in AD
Data analysis from a genome wide screening of Al~l ,ei. ner's paliel1ls (23), using 700 microsatellites (positioned at an average of 4 to 20 7 cM), reveals seven (excluding ApoE) different regions in the genome which seem to be implicated in the physiopathology of AD. Genetic markers representing these regions have been sorted with relative P
values, and are ordered from greatest importance as follows: D10S212 > D6S273 > D1S228 > D1S232 > Gata89a1 > D2S126 > ApoE >
25 D8S552. Other potential sites of interest have also been detected in the genomic regions containing the Presenilin gene which have previously been shown to be implicated in AD pathology. The P values for these regions, however, were found to be weaker than those observed for the microsatellites listed above.
The microsatellite D10S212 coincides with the region of principal interest as revealed by fine mapping, and is found to be adjacent 5 to an intron of the inositol polyphosphate-5-phosphatase gene (IPP1).
This gene encodes a 43-Kda protein involved in the inositol phosphate pathway, its role being that of a downregulator within the cascade by inactivating inositol phosphate signalling molecules.
Biochemical messengers within most cells effect diverse 10 and complex responses that often depend on the mobilization of Ca2 from intracellular stores within the sarcoplasmic (in muscle) or endoplasmic reticulum (S-ER). Two types of S-ER Ca2 stores have been functionally characterized and identified by immunocyto-chemical localization of receptors (reviewed by Golovina and Blaustein, 1997), and 15 release of Ca2 from one of the stores requires myo-inositol 1,4,5-trisphosphate (IP3).
Two distinct human genes coding for 5-phosphatase (Types I and ll) have been cloned, and encode for 43-kDa and 75-kDa proteins respectively. The Type I protein is phosphorylated and activated by 20 protein kinase C, while Type ll is not phosphorylated by this kinase. 5-phosphatase enzymes hydrolyze three substrates involved in calcium mobilization: inositol 1,4,5-triphosphate (IP3), inositol cyclic 1:2,4,5-tetrakisphosphate and inositol 1,3,4,5-tetrakisphosphate (IP4).
The published cDNA of the inositol polyphosphate-5-phosphatase (IPP-1 ) is not complete, but we have cloned the full length cDNA from a humain brain cDNA library as well as part of the promoter ~ CA 02203083 1997-04-18 region, and have determined the intron/exon junction sequences. The genomic DNA corresponding to the exons and intron/exon junctions of the gene have been amplified using PCR and screened for mutations by the method of single strand conformation polymorphism (SSCP), from which 5 some nucleotide changes have been observed. All the polymorphisms except one are found within non-coding sequences, or in the third codon position in exons, which do not alter the amino acid residue. The only non- conservative mutation found is within the third exon of the gene, which changes the amino acid Iysine (MG) to arginine (AGG). However, 10 this transition is conservative if we consider the presence of a putative phosphorylation consensus sequence serine/threonine-X-lysine/arginine at that site. Experiments employing RT-PCR to analyze this polymorphism on the basis of differential expressio" levels within a set of patient samples did not show any differences.
Several studies suggest that alterations in the receptor-mediated phosphoinositide casc~de and cytosolic free calcium conceril,dlion [Ca2+]j are involved in the pathophysiology of aging, and in Alzheimer's disease. Cellular calcium ion signalling is induced by inositol phosphates formed directly or indirectly by the action of 20 phosphatidylinositol-specific phospholipase C on phosphdlidylinositol 4,5-bisphosphate in response to extracellular agonists (Berridge and Irvine, 1989; Bansal and Majerus, 1990; Rana and Hokin, 1990). These inositol phosphate signaling molecules are inactivated by inositol polyphosphate-5-phosphatase enzymes (5-phosphatase). Thus, by analogy with the 25 adenylate cyclase/cyclic nucleotide phosphodiesterase system (Ross and Gilman, 1990), phospholipase C forms the active signalling molecules, while the 5-phosphatase acts to degrade them. Changes in the activity of either of these enzymes may alter cellular responses to agonists.
One or more components of the inositol pathway are thus considered as excellent candidates for the development of a physiopathological model of Alzheimer disease. In light of the fact that the IP3R1-/- (from human chromosome 1) transgenic mice develop epilepsy, and that studies on human families affected by the JME reveal that the affected loci cosegregate with chromosome 6p21 where the homolog gene (IP3R3) is located, it appears highly probable that alterations in this pathway could be shared by different forms of genetic neurodisorders. If this proposed scenario is correct, we would expect to find in our population of AD some incidence of epilepsy, and this is indeed the case; the incidence of epilepsy in our examined population is signihcantly higher than that normally expected. These observations point tantilizingly towards the hypothesis that various alterations within the inositol biochemical pathway may result in vastly differing phenotypic manifestations, including epilepsy and Alzheimer's disease.
The 5-phospl1atase gene present on chromosome 10 was cloned and its cDNA and gene sequence is shown in Fig. 1.
The present invention therefore provides sequences of the human Type 1 5-phosphatase (IPP-1) and products thereof for diagnosis and l,eal"~e"l of CNS disorders such as AD. Having identified this gene from human, homologs thereof can be identified and isolated from other animals. Such homologs could also be used in accordance with thye present invention.
The present description refers to a number of documents, the contents of which are incorporated by reference.
~ CA 02203083 1997-04-18 REFERENCES
M.J.Berridge, R.F.lrvine. Inositol phosphates and cell signalling. Nature 341:197-205,1989.
V.A. Golovina, M.P.Blaustein. Spatially and functionally distinct Ca+
stores in sarcoplasmic and endoplasmic reticulum. Science 275:1643-1648, 1997.
10 K.M. Laxminarayan, B.K. Chan,T.Tetaz, P.l. Bird, C.A. Mitchell.
Characterization of a cDNA encoding the 43-kDa membrane-associated inositol-polyphosphate 5-phosphatase. J. Biol. Chem. 269: 17305-17310, 1994.
15 A.W. Liu, A.V. Delgado-Escueta, J.M. Serratosa, M.E. Alonso, M.T.
Medina, M.N. Gee, S. Cordova, H.Z. Zhao, J.M. Spellman, J.R. Ramos Peek, F. Rubio Donnadieu, R.S.Sparkes. Juvenile Myoclonic Epilepsy locus in chromosome 6p21.2-p11: Linkage to convulsions and electroencephalography trait. Am.J.Hum.Genet. 57:368-381, 1995.
A.R. Maranto. Primary structure, ligand binding, and localization of the human type 3 Inositol 1,4,5-Trisphosphate Receptor expressed in i"tesli"al epithelium. J. Biol. Chem 269:1222-1230,1994.
25 M. Matsumoto, T. Nakagawa, T. Inoue, E. Nagata, K. Tanaka, H. Takano, O. Minowa, J. Kuno, S. Sakakibara, M. Yamada, H. Yoneshima, A.
Miyawaki, Y. Fukuuchi, T. Furuichi, H. Okano, K. Mikoshiba, T. Noda.
Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature 379; 168-171,1996.
T.S. Ross, A.B. Jefferson, C.A. Mitchell, P.W. Majerus. Cloning and expression of human 75-kDa Inositol Polyphosphate-5-phosphatase. J.
Biol. Chem. 266:20283-20289, 1991.
35 M. Yamamoto-Hino, T. Sugiyama, K. Hikichi, M.G. Mattei, K. Hasegawa, S. Sekine, K. Sakurada, A. Miyawaki, T. Furuichi, M. Hasegawa, K.Mikoshiba. Cloning and characterization of human type 2 and type 3 Inositol 1,4,5-Trisphosphate receptors. Receptors and Channels 2:9-22, 1994.
. CA 02203083 1997-04-18 L.T. Young, S.J. Kish,P.P. Li, J.J. Warsh. Decreased brain H3 inositol 1,4,5-trisphosphate binding in Alzheimer's disease. Neuroscience Letters, 94: 198-202,1988.
5 M. C. Chartier-Harlin, F. Crawford, H. Houlden, A. Warren, D. Hughes, L.
Fidani, A. Goate, M. Rossor, P. Roques, J. Hardy ef al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 353: 844-846 (1991).
10 E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C.
Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance.
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921 -923 (1993).
15 L. Fidani, K. Rooke, M. C. Chartier-Harlin, D. Hughes, R. Tanzi, M.
Mullan, P. Roques, M. Rossor, J. Hardy, A. Goate. Screening for mutations in the open reading frame and pro",oter of the beta-amyloid precursor protein gene in familial Alzheimer's disease: idenlific~lion of a further family with APP717 Val-~lle. Hum. Mol. Genet. 1: 165-168 (1992).
G. G. Glenner, C. W. Wong. Alzheimer's disease: initial report of the purification and chara~;te,i~dlion of a novel cerebrov~scul~r amyloid protein. Biochem. Biophys. Res. Commun.120: 885-890 (1984).
A. Goate, M. C. Chartier-Harlin, M. Mullan, J. Brown, F. Crawford, L.
Fidani, L. Giuffra, A. Haynes, N. Irving, L. James ef al. Segr~yalion of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706 (1991).
J. Kang, H. G. Lemaire, A. Unterbeck, J. M. Salbaum, C. L. Masters, K.
H. Grzeschik, G. Multhaup, K. Beyreuther, B. Muller-Hill. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736 (1987).
H. Karlinsky, G. Vaula, J. L. Haines, J. Ridgley, C. Bergeron, M. Mortilla, R. G. Tupler, M. E. Percy, Y. Robitaille, N. E. Noldy et a/. Molecular and prospective phenotypic characterization of a pedigree with familial Alzheimer's disease and a missense mutation in codon 717 of the beta-amyloid precursor protein gene. Neurology 42: 1445-1453 (1992).
' CA 02203083 1997-04-18 H. G. Lemaire, J. M. Salbaum, G. Multhaup, J. Kang, R. M. Bayney, A.
Unterbeck, K. Beyreuther, B. Muller-Hill. The PreA4(695) precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons.
Nucleic Acids Res. 17: 517-522 (1989).
E. Levy-Lahad, E. M. Wjsman, E. Nemens, L. Anderson, K. A. Goddard, J. L. Weber, T. D. Bird and G. D. Schellenberg. A familial Alzheimer's disease locus on chromosome 1. Science 269: 970-973 (1995a) 10 E. Levy-Lahad, W. Wasco, P. Poorkaj, D. M. Romano, J. Oshima, W. H.
Pettingell, C. E. Yu, P. D. Jondro, S. D. Schmidt, K. Wang et al.
Candidate gene for the chromosome 1 ramilial Alzheimer's disease locus.
Science 269: 973-977 (1995b).
15 C. L. Masters, G. Simms, N. A. Weinman, G. Multhaup, B. L. McDonald, K. Beyreuther. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U S A 82: 4245-9. (1985).
M. Mullan, H. Houlden, M. Windelspecht, L. Fidani, C. Lombardi, P. Diaz, 20 M. Rossor, R. Crook, J. Hardy, K. Duff et al. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat. Genet. 2: 340-342 (1992).
J. Murrell, M. Farlow, B. Ghetti, M. D. Benson. A mutation in the amyloid 25 precursor protein associated with hereditary Alzheimer's disease.
Science 254: 97-99 (1991).
S. Naruse, S. lgarashi, H. Kobayashi, K. Aoki, T. Inuzuka, K. Kaneko, T.
Shimizu, K. Iihara, T. Kojima, T. Miyatake etal. Mis-sense mutation Val-30 lle in exon 17 of amyloid precursor protein gene in Japanese familialAlzheimer'sdisease. Lancet337:978-979 (1991).
M. A. Pericak-Vance, J. L. Bebout, P. C. Gaskell, L. H. Yamaoka, W. Y.
Hung, M. J. Alberts, A. P. Walker, R. J. Bartlett, C. A. Haynes, K. A.
35 Welsh et al. Linkage studies in familial Alzheimer disease: evidence for chromosome19 linkage. Am J Hum Genet 48: 1034-50 (1991).
E. l. Rogaev, R. Sherrington, E. A. Rogaeva, G. Levesque, M. Ikeda, Y.
Liang, H. Chi, C. Lin, K. Holman, T. Tsuda et al. Familial Alzheimer's 40 disease in kindreds with missense mutations in a gene on chromosome , CA 02203083 1997-04-18 -1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778 (1995).
G. D. Schellenberg, T. D. Bird, E. M. Wijsman, H. T. Orr, L. Anderson, E.
5 Nemens, J. A. White, L. Bonnycastle, J. L. Weber, M. E. Alonso et al.
Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science 258: 668-671 (1992).
10 R. Sherrington, E. l. Rogaev, Y. Liang, E. A. Rogaeva, G. Levesque, M.
Ikeda, H. Chi, C. Lin, G. Li, K. Holman et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760 (1995) 15 C. van Broeckhoven. Presenilins and Alzheimer's disease. Nat. Genet.
11: 230-232 (1995).
Claims (2)
1. A nucleic acid sequence encoding IPP-1 for diagnosing and/or treating Alzheimer's disease.
2. A nucleic acid sequence as set forth in Fig. 1, complemenary sequence thereof or sequence hybridizing thereto under stringent conditions.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2203083 CA2203083A1 (en) | 1997-04-18 | 1997-04-18 | Gene and cdna involved in alzheimer's disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA 2203083 CA2203083A1 (en) | 1997-04-18 | 1997-04-18 | Gene and cdna involved in alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2203083A1 true CA2203083A1 (en) | 1998-10-18 |
Family
ID=4160470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2203083 Abandoned CA2203083A1 (en) | 1997-04-18 | 1997-04-18 | Gene and cdna involved in alzheimer's disease |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2203083A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064730A1 (en) * | 2000-03-02 | 2001-09-07 | Biowindow Gene Development Inc. Shanghai | A novel polypeptide, human 5-phosphatase 18 and the polynucleotide encoding thereof |
EP1404863A1 (en) * | 2001-06-05 | 2004-04-07 | Exelixis, Inc. | PIBs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
-
1997
- 1997-04-18 CA CA 2203083 patent/CA2203083A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001064730A1 (en) * | 2000-03-02 | 2001-09-07 | Biowindow Gene Development Inc. Shanghai | A novel polypeptide, human 5-phosphatase 18 and the polynucleotide encoding thereof |
EP1404863A1 (en) * | 2001-06-05 | 2004-04-07 | Exelixis, Inc. | PIBs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
EP1404863A4 (en) * | 2001-06-05 | 2005-05-11 | Exelixis Inc | PIBs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180010190A1 (en) | Genetic variant of the annexin a5 gene | |
US20040132021A1 (en) | Osteolevin gene polymorphisms | |
AU2006225995B2 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof | |
EP1377678A2 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
WO2003076658A2 (en) | A susceptibility gene for late-onset idiopathic parkinson's disease | |
CA2203083A1 (en) | Gene and cdna involved in alzheimer's disease | |
US20060141462A1 (en) | Human type II diabetes gene-slit-3 located on chromosome 5q35 | |
WO2003064471A2 (en) | Gene for peripheral arterial occlusive disease | |
CA2203084A1 (en) | The inositol phosphate pathway and its implication in alzheimer's disease | |
EP0811695A2 (en) | Mutant S182(PS-1) genes | |
US6083694A (en) | Method for elucidation and detection of polymorphisms, splice variants, and proximal coding mutations using intronic sequences of the alzheimer's S182 gene | |
CA2203070A1 (en) | Chromosome 6 gene and gene products related to alzheimer's disease | |
CA2203071A1 (en) | Chromosome 10 gene and gene products related to alzheimer's disease | |
WO1996032502A1 (en) | Reagent specific for apolipoprotein-j polymorphisms and uses thereof | |
Hardy et al. | Genetic variability and Alzheimer’s disease | |
US20050048492A1 (en) | Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determining cyp46 genotype | |
US20150031569A1 (en) | Mutations of the GPR179 Gene in Congenital Stationary Night Blindness | |
CA2203069A1 (en) | Chromosome 12 gene and gene products related to alzheimer's disease | |
CA2203072A1 (en) | Chromosomal markers related to alzheimer's disease | |
CA2203068A1 (en) | Chromosome 1p gene and gene products related to alzheimer's disease | |
US20050130165A1 (en) | Polymorphism of soati useful for identifying risk of developing alzheimer's disease | |
CA2203085A1 (en) | 5-phosphatase type-ii and implication in alzheimer's disease | |
EP0833947A1 (en) | Variant presenilin-2 genes | |
US20020182669A1 (en) | GPI-anchored small leucine-rich proteoglycan gene NYX | |
Class et al. | Patent application title: FAM26C POLYMORPHISMS AND USE THEREOF FOR THE DIAGNOSTIC AND TREATMENT OF LATE ONSET ALZHEIMER'S DISEASE Inventors: Philippe Marambaud (Astoria, NY, US) Fabien Campagne (Astoria, NY, US) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |